That is the key , I think the previous success of RAP from 2c and continued price rise since last year , the market will be interested to know what story is next , and with advanced testing and a stated milestone for performance shares upon commercialisation of a product within 12 months I believe the market will like the epat story and I believe a continued rise in market cap will happen as commercialisation is not far away, like all performance shares the smart ones set them so they are achievable , afterall as management why wouldn't you want more stock
The other key point which is a factor I rate highly with companies is the calibre of the management team , having met them at the general meeting and reading their CVs I am impressed that they have joined, which my sense was they believe it can be a real winner , but having this calibre talking when doing roadshows and being based in Sydney means that broking houses and funds will sit up and listen.
yes you will get those happy to have bought and sold in a week but as you mentioned the real money made is the holders of a good story like long term holders of RAP have enjoyed , and you only need to find a handful of those to hang onto
Then it's the multiple uses of the epat technology for instance next year the anticipation will be they have a prototype for the kids app, I think that globally this will be huge as parents want the best information for caring of their kids
Will be interesting what epat does by Christmas time, market cap wise
- Forums
- ASX - By Stock
- News flow
That is the key , I think the previous success of RAP from 2c...
-
-
- There are more pages in this discussion • 16 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MNQ (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Will Souter, CFO
Will Souter
CFO
Previous Video
Next Video
SPONSORED BY The Market Online